209 related articles for article (PubMed ID: 33391473)
1. Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Jiang T; Jiang L; Dong X; Gu K; Pan Y; Shi Q; Zhang G; Wang H; Zhang X; Yang N; Li Y; Xiong J; Yi T; Peng M; Song Y; Fan Y; Cui J; Chen G; Tan W; Zang A; Guo Q; Zhao G; Wang Z; He J; Yao W; Wu X; Chen K; Hu X; Hu C; Yue L; Jiang D; Wang G; Liu J; Yu G; Li J; Zhang H; Wu L; Fang L; Liang D; Zhao Y; Zhao W; Xie W; Ren S; Zhou C
Theranostics; 2021; 11(1):257-267. PubMed ID: 33391473
[No Abstract] [Full Text] [Related]
2. Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.
Jiang T; Li X; Wang J; Su C; Han W; Zhao C; Wu F; Gao G; Li W; Chen X; Li J; Zhou F; Zhao J; Cai W; Zhang H; Du B; Zhang J; Ren S; Zhou C; Yu H; Hirsch FR
Theranostics; 2017; 7(19):4753-4762. PubMed ID: 29187901
[No Abstract] [Full Text] [Related]
3. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
[TBL] [Abstract][Full Text] [Related]
5. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients.
Zhou X; Li C; Zhang Z; Li DY; Du J; Ding P; Meng H; Xu H; Li R; Ho E; Zhang A; Okunieff P; Lu J; Sha MY
Sci Rep; 2021 Apr; 11(1):7633. PubMed ID: 33828112
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y
World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
9. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
10. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
Wang Z; Huang C; Yang JJ; Song Y; Cheng Y; Chen GY; Yan HH; Ben XS; Wang BC; Xu CR; Jiang BY; Zhou Q; Chen HJ; Wu YL
Eur J Cancer; 2019 Mar; 109():183-191. PubMed ID: 30739019
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Najjar F; Alammar M; Bachour M; Almalla N; Altahan M; Alali A; Al-Massarani G
J Cancer Res Clin Oncol; 2015 Jan; 141(1):119-25. PubMed ID: 25037116
[TBL] [Abstract][Full Text] [Related]
12. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Ren S; Zhou S; Wu F; Zhang L; Li X; Zhang J; Xu J; Lv M; Zhang J; Zhou C
Lung Cancer; 2012 Jan; 75(1):102-9. PubMed ID: 21676483
[TBL] [Abstract][Full Text] [Related]
13. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract][Full Text] [Related]
15. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Iranzo V; Sirera R; Carrato A; Cabrera A; Jantus E; Guijarro R; Sanmartín E; Blasco A; Gil M; Gómez-Aldaraví L; González-Larriba JL; Massuti B; Velasco A; Provencio M; Rossell R; Camps C
Clin Transl Oncol; 2011 Jun; 13(6):411-8. PubMed ID: 21680302
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
Yang JJ; Huang C; Chen GY; Song Y; Cheng Y; Yan HH; Zhou Q; Wu YL
BMC Cancer; 2014 Sep; 14():684. PubMed ID: 25239521
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
19. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
[TBL] [Abstract][Full Text] [Related]
20. Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Hu L; Liang G; Yuliang W; Bingjing Z; Xiangdong Z; Rufu X
Trials; 2013 Feb; 14():45. PubMed ID: 23413951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
